Welcome to our dedicated page for PROCTER & GAMBLE Co SEC filings (Ticker: PG), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on PROCTER & GAMBLE Co's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into PROCTER & GAMBLE Co's regulatory disclosures and financial reporting.
Procter & Gamble (PG) insider activity: Chief Operating Officer Shailesh Jejurikar reported acquisition and disposition of company common stock and RSUs. On 08/18/2025 he was awarded 31,025 shares under the companys 2019 Stock and Incentive Compensation Plan and received dividend-equivalent RSUs settled in stock, bringing his total beneficial ownership to 41,075.3817 shares. On 08/19/2025 he sold 13,039 shares at $157.2738 per share to cover taxes related to the stock award, leaving 28,036.3817 shares held directly. Additional indirect holdings include 3,301.9815 shares via a retirement plan trustee and trusts holding 19,757 and 17,849 shares respectively. The filing was signed by an attorney-in-fact on 08/20/2025.
Matthew W. Janzaruk, Senior Vice President and Chief Accounting Officer of Procter & Gamble Company (PG), reported two transactions in August 2025. On 08/18/2025 he received a stock award of 1,044 shares issued under the company's 2019 Stock and Incentive Compensation Plan at no cash price, including dividend equivalents settled as restricted stock units that increased his holdings. On 08/19/2025 he sold 319 shares at $157.2738 per share to cover taxes related to the award. After these transactions his direct beneficial ownership is reported as 1,703.9031 shares and he has 3,258.3804 shares indirectly held by a retirement plan trustee. The Form 4 was signed on behalf of Mr. Janzaruk by an attorney-in-fact on 08/20/2025.
Procter & Gamble (PG) insider filing shows stock award and routine tax sale by an officer. The reporting person, Ma. Fatima Francisco, an officer (CEO - Baby, Fem & Family Care), received a stock award of 22,649 shares on 08/18/2025 under the issuer's 2019 Stock and Incentive Compensation Plan, including dividend-equivalent RSUs. On 08/19/2025 she sold 9,100 shares at $157.2738 per share to cover taxes. Following these transactions, she beneficially owns 36,395.0856 shares directly and an additional 18,696.015 shares indirectly (15,866.8034 via retirement plan trustee and 2,829.2115 via spouse/retirement trustees). A small RSU grant of 50.2079 units was also reported.
Jennifer L. Davis, an officer (CEO - Health Care) of Procter & Gamble Co. (PG), reported transactions on Form 4 showing grants and awards of company common stock and restricted stock units. On 08/18/2025 she acquired 21,518 shares via a stock award under the issuer's 2019 Stock and Incentive Compensation Plan at a reported price of $0, bringing her total beneficial ownership to 73,586.9326 shares (the total includes dividend equivalents settled in common stock). The filing also shows 15,401.6828 shares held indirectly by a retirement plan trustee and the acquisition of 24.9443 restricted stock units (RSUs) on 08/15/2025 that will convert to shares on retirement or be deferred into a compensation account. The document is signed by an attorney-in-fact on behalf of Ms. Davis on 08/20/2025.
Form 144 notice for Procter & Gamble Company (PG) shows a proposed sale of Common Stock scheduled on 08/21/2025 through Morgan Stanley Smith Barney LLC Executive Financial Services on the NYSE. Two separate lots are listed: 796 shares with an aggregate market value of $125,119.26 and 11,128 shares with an aggregate market value of $1,749,154.68, for a combined market value of $1,874,273.94. The securities were acquired on 08/18/2025 as Performance Stock Program Awards from The Procter & Gamble Company; amounts acquired were 1,725 and 24,091 shares respectively, with payment dates on 08/18/2025. The filer reports no securities sold in the past three months and includes the standard signature representations required by Rule 144.
Procter & Gamble Company (PG) Form 144 notice reports a proposed sale of 7,230 shares of common stock through Morgan Stanley Smith Barney LLC on 08/19/2025 with an aggregate market value of $1,119,963.15. The shares were acquired the prior day, 08/18/2025, as a Performance Stock Program Award from The Procter & Gamble Company and payment was recorded on 08/18/2025. The filing lists total shares outstanding as 2,342,371,488. The filer certifies no undisclosed material adverse information and provides signature and legal attestations required by the form.
Form 144 notice from an insider at The Procter & Gamble Company (PG) reports a proposed sale of 11,578 shares of common stock through Morgan Stanley Smith Barney LLC on the NYSE, with an aggregate market value of $1,793,490.09 and approximately 2,342,371,488 shares outstanding. The securities were acquired on 08/18/2025 as a Performance Stock Program Award and payment was recorded on the same date. The filer states there have been no sales by the person in the past three months and affirms no undisclosed material adverse information is known. This filing is a routine Rule 144 notice indicating the intention to sell company shares by an insider and does not include broader financial results or operational details.
Procter & Gamble Company (PG) filing a Form 144 notifies the proposed sale of 13,677 shares of common stock through Morgan Stanley Smith Barney LLC on the NYSE with an aggregate market value of $2,118,635.69. The shares were acquired on 08/18/2025 as a Performance Stock Program Award from The Procter & Gamble Company and payment/vesting is recorded on 08/18/2025. The approximate date of sale listed is 08/19/2025. The filer indicates there have been no sales in the past three months and attests to possessing no undisclosed material adverse information.
Procter & Gamble Company (PG) Form 144 notice discloses a proposed sale of 12,353 shares of common stock through Morgan Stanley Smith Barney LLC with an aggregate market value of $1,913,541.47. The shares are reported as acquired on 08/18/2025 under a Performance Stock Program Award from The Procter & Gamble Company, with an approximate sale date of 08/19/2025. The filing lists 2,342,371,488 shares outstanding for the class. No securities of the issuer were reported sold by the person in the prior three months. The filer represents there is no undisclosed material adverse information and notes the criminal penalties for misstatement.
The filing is a Form 144 notice reporting a proposed sale of 10,094 shares of Procter & Gamble Company common stock through Morgan Stanley Smith Barney LLC on the New York Stock Exchange, with an aggregate market value of $1,563,611.07, and an approximate sale date of 08/19/2025. The shares were acquired on 08/18/2025 under a Performance Stock Program Award from Procter & Gamble and 21,372 shares are shown as the amount acquired on that date for the award. The filer represents they are not aware of any undisclosed material adverse information about the issuer.